-transparent.png){kind=logo}
We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET.
Related Publications
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
August 1987,
Southern medical journal,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
October 1989,
Acta pathologica japonica,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
April 1984,
Blood,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
August 1997,
Genes, chromosomes & cancer,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
December 2006,
Clinical nuclear medicine,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
January 1990,
Haematologica,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
January 1996,
European journal of haematology,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
December 2014,
Future oncology (London, England),
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
March 2009,
Haematologica,
Y Asano, and
Y Naritomi, and
H Kimura, and
Y Maeda, and
T Kusaba, and
S Yoshizawa, and
G Shiraishi
February 1996,
JPMA. The Journal of the Pakistan Medical Association,
